Armata Pharmaceuticals, Inc.
ARMP
$1.42
$0.06815.04%
AMEX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 1.24M | 2.97M | -- | 966.00K | 1.53M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.24M | 2.97M | -- | 966.00K | 1.53M |
| Cost of Revenue | 33.73M | 323.00K | 8.48M | 8.02M | 32.82M |
| Gross Profit | -32.49M | 2.65M | -8.48M | -7.05M | -31.29M |
| SG&A Expenses | 3.32M | 3.24M | 3.44M | 3.18M | 3.18M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.77M | 12.73M | 11.91M | 11.19M | 11.11M |
| Operating Income | -10.54M | -9.76M | -11.91M | -10.23M | -9.58M |
| Income Before Tax | 2.60M | -5.48M | 8.99M | -25.02M | -19.85M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 2.60M | -5.48M | 8.99M | -25.02M | -19.85M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 2.60M | -5.48M | 8.99M | -25.02M | -19.85M |
| EBIT | -10.54M | -9.76M | -11.91M | -10.23M | -9.58M |
| EBITDA | -10.16M | -9.44M | -11.60M | -9.91M | -9.29M |
| EPS Basic | 0.07 | -0.15 | 0.25 | -0.69 | -0.55 |
| Normalized Basic EPS | -0.24 | -0.21 | -0.25 | -0.21 | -0.19 |
| EPS Diluted | -0.52 | -0.15 | -0.25 | -0.69 | -0.55 |
| Normalized Diluted EPS | -0.14 | -0.21 | -0.15 | -0.21 | -0.19 |
| Average Basic Shares Outstanding | 36.18M | 36.18M | 36.15M | 36.13M | 36.10M |
| Average Diluted Shares Outstanding | 59.08M | 36.18M | 58.25M | 36.13M | 36.10M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |